Main Menu

Translational Oncogenomics Team

Dr Marco Gerlinger's team investigates how cancer evolution and plasticity lead to resistance to cancer drugs and immunotherapies, with the aim of designing better treatments that prevent drug resistance.

Team leader

Dr Marco Gerlinger

Dr Marco Gerlinger

Dr Marco Gerlinger develops new tools to detect and track the evolution of cancer cells and of their microenvironment and better therapies which prevent the evolution of drug resistance. He holds an Honorary Consultant Medical Oncologist position at The Royal Marsden NHS Foundation Trust, where he treats patients with gastro-intestinal cancers. Based on the research in his lab, he performs clinical trials of novel immunotherapies that aim to leverage the immune system to attack cancer cells.

ORCID 0000-0003-2719-299X

Team members

Dr Louise Barber

Higher Scientific Officer

Dr Ben Challoner

PhD Student

Dr Caroline Fong

Clinical Fellow

Beatrice Griffiths

Higher Scientific Officer

Dr Franciele Knebel

Postdoctoral Fellow

Alice Newey

PhD Student

Maria Semiannikova

PhD Student

Renske van Boxtel

BSc Student

Dr Andrew Woolston